Hence, we tried to find the novel chemical inhibitor against JAK2 as the therapeutic way to treat RCC by screening an FDA-approved drug library (821 drugs) with a JAK2 kinase assay kit. This evidence concerns the gene JAK2 and renal cell carcinoma.